dr. bendell on fda approval of regorafenib in liver cancer
Published 7 years ago • 287 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
0:49
dr. bendell on remaining questions with regorafenib in hcc
-
1:27
dr. sherman on the role of regorafenib in liver cancer
-
5:31
practical advice for using regorafenib
-
1:47
dr. jordi bruix on the impact regorafenib will have on liver cancer treatment
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
0:42
dr. keedy on regorafenib for the treatment of gist
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
0:52
dr. bendell on a phase ii study of onartuzumab in combination with bevacizumab for mcrc
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
0:49
dr. daniele on impact of regorafenib in hcc
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:49
fda approval of durvalumab for bladder cancer
-
9:34
regorafenib in colorectal cancer
-
1:34
dr. finn on the promise of regorafenib for the treatment of hcc
-
11:24
managing toxicities associated with regorafenib
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
3:14
when you have decided to prescribe regorafenib
-
6:39
emerging second-line therapies in hcc